In eastern Africa, an algorithm proves capable of aiding brain-injured patients

Researchers at Duke and in Tanzania have developed an algorithm for discerning the extent of a traumatic brain injury (TBI) in a low-resource setting.

Their hope is that the tool will improve triage and other care decisions—and thus outcomes—in underdeveloped parts of the world, where a brain injury is too often an avoidable calamity, according to a study published online in the Journal of Neurosurgery.

Psychologist João Ricardo Vissoci, PhD, of Duke’s Global Health Institute, emergency physician Francis Sakita of the Kilimanjaro Christian Medical Centre and colleagues used data from a registry of 3,138 Tanzanian TBI patients to train and test nine separate machine-learning techniques.

They included data on demographics, vital signs, injury type and treatment received.

The best of the nine algorithms attained an accuracy score well within the range of “good,” while even the worst-performing tool was poor but not a failure.

The team found the key predictors of a good outcome were increasing coma-scale score, increasing blood-oxygen levels and undergoing TBI surgery.

Poor outcomes were most likely in patients who were older and suffered their TBIs in a vehicular crash.

“Limited access to diagnostic technologies and highly skilled providers, combined with high patient volumes, contributes to poor outcomes in low- and middle-income countries,” the authors concluded. “Prognostic modeling as a clinical decision support tool, in theory, could optimize the use of existing resources and support timely treatment decisions in [these regions].”

They underscored that the study’s main achievement was developing a TBI prognostic model “with a substantial level of accuracy in a low-resource setting,” adding that further research is needed to validate and test their technique as a clinical decision support tool.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.